Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Extracorporeal Photopheresis as a Possible Therapeutic Approach to Adults With Severe and Critical COVID-19 Non-responsive to Remdesivir, Dexamethasone and Pharmacological Immunomodulation: an Investigational Study

NCT05882331 is registered in ClinicalTrials.gov with Del-Pest Central Hospital - National Institute of Hematology and Infectious Diseases as lead sponsor.

NCT NCT05882331
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05882331 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Extracorporeal Photopheresis as a Possible Therapeutic Approach to Adults With Severe and Critical COVID-19 Non-responsive to Remdesivir, Dexamethasone and Pharmacological Immunomodulation: an Investigational Study
Lead sponsor
Del-Pest Central Hospital - National Institute of Hematology and Infectious Diseases
Phase
Not applicable
Overall status
Completed
Start date
January 1, 2021
Completion date
August 6, 2024
Enrollment
7 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19